Studies involving disease:Malaria

Study ID Study Title Species Institute
ST000414Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of actionPlasmodium falciparumMonash Institute of Pharmaceutical Sciences
ST000441Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target PathwaysPlasmodium falciparumPennsylvania State University
ST000546Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant PlasmodiumPlasmodium falciparumMonash University
ST000578Experiment HuA: Metabolomics of plasma samples from humans infected with Plasmodium vivax strain.HumanEmory University
ST000592Uninfected Macaca mulatta exposed to pyrimethamine to produce and integrate clinical, hematological, and omics control measures.Rhesus monkeyEmory University
ST000599Metabolomics measures of Macaca mulatta infected with Plasmodium coatneyi Hackeri strainRhesus monkeyEmory University
ST001033Determination of mode of action of anti-malalrial drugs using untargeted metabolomicsPlasmodium falciparumMonash University
ST001149Plasmodium Niemann-Pick Type C1-Related Protein is a Druggable Target Required for Parasite Membrane HomeostasisPlasmodium falciparumPennsylvania State University
ST001175Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparumPlasmodium falciparumMonash University
ST001188P. falciparum infected erythrocytesPlasmodium falciparumUniversity of Melbourne
ST001201Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasitesHumanMonash University
ST001201Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasitesPlasmodium falciparumMonash University
ST001202Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasitesHumanMonash University
ST001202Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasitesPlasmodium falciparumMonash University
ST001204Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasitesHumanMonash University
ST001204Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasitesPlasmodium falciparumMonash University
ST001205Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasitesHumanMonash University
ST001205Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasitesPlasmodium falciparumMonash University
ST001232Combining stage - specificity and metabolomic profiling to advance drug discovery for malariaPlasmodium falciparumPennsylvania State University
ST001238P falciparum asexual metabolomics following drug treatment (part-I)Plasmodium falciparumPennsylvania State University
ST001239NMR assignment of synthetic pantothenamides (part-II)SyntheticPennsylvania State University
ST001279K13 mutations driving artemisinin resistance rewrite Plasmodium falciparum’s programmed intra-erythrocytic development and transform mitochondrial physiologyPlasmodium falciparumPennsylvania State University
ST001315Retargeting azithromycin-like compounds as antimalarials with dual modalityPlasmodium falciparumMonash University
ST001384Plasmodium falciparum increased time in circulation underlies persistent asymptomatic infection in the dry seasonHumanPennsylvania State University
ST001400Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malariaHumanNew York University Abu Dhabi
ST001516Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-II)HumanNew York University Abu Dhabi
ST001517Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-III)HumanNew York University Abu Dhabi
ST001652Atypical Molecular Basis for Drug Resistance to Mitochondrial AQ: A Function Inhibitors in Plasmodium falciparumPlasmodium falciparumU.S. Food & Drug Administration
ST001660Plasmodium falciparum metabolomics as a result of treatment with putative acetyl-CoA synthetase inhibitorsPlasmodium falciparumPennsylvania State University
ST001775Plasma metabolomics of diverse mouse strains infected with Plasmodium chabaudiMouseStanford University
ST001864Targeting host glycolysis as a strategy for antimalarial developmentHumanUniversity of Colorado Anschutz Medical Campus
ST001985Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183HumanPennsylvania State University
ST001985Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183Plasmodium falciparumPennsylvania State University
ST002011The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases.Plasmodium falciparumPennsylvania State University
ST002024Plasmodium falciparum stable-isotope carbon labeling to explore metabolic consequences of keto–acid dehydrogenase disruptionPlasmodium falciparumPennsylvania State University
ST002078Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target.Plasmodium falciparumPennsylvania State University
ST002106Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1)Plasmodium falciparumMonash University
ST002107Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2)Plasmodium falciparumMonash University
ST002108Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3)Plasmodium falciparumMonash University
ST002181Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages.Plasmodium falciparumPennsylvania State University
ST002309Targeting malaria parasites with novel derivatives of azithromycinPlasmodium falciparumMonash University

Return to search page
  logo